The Biggest Cancer Research Breakthroughs of 2025: What They Mean for Patients
- Dr. Tobias Kohler
- Jun 7
- 7 min read
2025 has been a genuinely remarkable year for cancer research. From AI systems that can predict which patients will respond to immunotherapy using a routine blood test, to personalised mRNA cancer vaccines showing durable responses, to off-the-shelf immune cell therapies achieving 80% response rates in early trials — the pace of progress has been extraordinary.
This article is a factual overview of the most significant cancer research and treatment advances of 2025, drawing on published clinical trial data, FDA approvals, and findings from leading cancer centres including Memorial Sloan Kettering, MD Anderson, and the Breast Cancer Research Foundation.
These are not speculative findings — they are peer-reviewed results from clinical trials and regulatory decisions that are already shaping how cancer is treated.
1. AI Predicts Immunotherapy Response From a Routine Blood Test
One of the most clinically impactful findings of 2025 came from Memorial Sloan Kettering Cancer Center (MSK) and the Tisch Cancer Institute at Mount Sinai.
Researchers developed an artificial intelligence model called SCORPIO, designed to predict whether individual cancer patients will benefit from immune checkpoint inhibitors — currently one of the most important classes of cancer treatment. The critical breakthrough: SCORPIO works using only routine blood tests and standard clinical data, with no need for expensive genomic sequencing.
Published in January 2025 in Nature Medicine, the model was shown to outperform both of the current FDA-approved biomarkers used to predict checkpoint inhibitor response — PD-L1 expression and tumour mutational burden (TMB) — in accuracy and accessibility.
The significance is enormous. Checkpoint inhibitors are highly effective in some patients and ineffective in others, and current tools for predicting response are expensive, not universally available, and imperfect. A blood-test-based AI predictor could enable more precise treatment selection globally, reducing unnecessary exposure to immunotherapy side effects in patients unlikely to benefit.
2. mRNA Cancer Vaccines Show Durable Results
The same technology platform that produced the COVID-19 mRNA vaccines is now demonstrating promising results in cancer.
Moderna and Merck's personalised mRNA cancer vaccine (mRNA-4157/V940) showed impressive Phase 2b results in melanoma when combined with Pembrolizumab (Keytruda), a checkpoint inhibitor. The vaccine is personalised to each patient — next-generation sequencing identifies the unique mutations in an individual's tumour, and a personalised mRNA vaccine is manufactured to train the immune system to recognise those specific cancer proteins.
The Phase 2b KEYNOTE-942 trial showed that combination therapy reduced the risk of recurrence or death by 44% compared to Pembrolizumab alone in patients with high-risk resected melanoma. Phase 3 trials are now underway across multiple cancer types including non-small cell lung cancer and bladder cancer.
Additionally, data presented at ESMO 2025 showed that cancer patients who received mRNA COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after treatment — a finding that has prompted significant interest in the potential immune-activating properties of mRNA platforms beyond their direct vaccine targets.
3. Off-the-Shelf CAR NK Cell Therapy — 80% Response Rate in Lymphoma
CAR-T cell therapy — in which a patient's own T-cells are genetically engineered to attack cancer — is one of the most transformative cancer treatments developed in the last decade. But it has a major limitation: it is personalised to each patient, requiring weeks to manufacture, and is not available in an off-the-shelf format.
Research presented from MD Anderson Cancer Center in 2025 highlighted a significant step towards solving this problem. FT596, a CAR NK (Natural Killer) cell therapy derived from induced pluripotent stem cells (iPSCs) and engineered to attack B-cell lymphoma, demonstrated a promising safety profile and — strikingly — more than 80% of participants in a Phase I clinical trial showed significant clinical responses.
Unlike CAR-T cells, which must be manufactured from each patient's own cells, iPSC-derived CAR NK cells can be manufactured in large batches from a single donor and stored — making them available immediately, like a conventional medicine. If Phase II and III trials confirm these results, off-the-shelf CAR NK therapy could dramatically expand access to cellular immunotherapy, reducing waiting times and costs significantly.
4. New FDA-Approved Breast Cancer Treatment — Oral SERD Imlunestrant
The FDA approved Imlunestrant (brand name Inluriyo) in 2025 — a new oral selective estrogen receptor degrader (SERD) for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation, in patients whose cancer has progressed after at least one line of endocrine therapy.
ESR1 mutations are one of the most common mechanisms by which hormone receptor-positive breast cancers develop resistance to standard endocrine therapy (aromatase inhibitors like letrozole and anastrozole). ESR1-mutated breast cancer has historically been difficult to treat — and imlunestrant provides a new targeted option specifically for this molecular subtype.
The approval represents the increasing precision of cancer treatment — moving from broad hormone-blocking therapies to medicines designed for specific molecular resistance mechanisms. A second oral SERD, Giredestrant, also received FDA fast-track designation in 2025 with promising clinical trial data.
5. Lorlatinib CROWN Study — Over Five Years Median Survival in Lung Cancer
For patients with ALK-positive non-small cell lung cancer (NSCLC), one of the most striking data readouts of 2025 came from the CROWN study of Lorlatinib — a third-generation ALK inhibitor.
The updated CROWN study results showed a median progression-free survival of over five years with Lorlatinib as a first-line treatment for ALK-positive NSCLC. For context, this is a cancer that historically had a prognosis measured in months without targeted therapy. Five years of progression-free survival in metastatic lung cancer represents a profound shift in the natural history of this disease for patients with the ALK mutation.
As Dr. Jyoti Malhotra, a medical oncologist, noted at the 2025 Seattle Lung Cancer Conference: "The CROWN study showed a median survival of more than five years with Lorlatinib for ALK-positive non-small cell lung cancer, which is a major milestone."
This finding reinforces the critical importance of molecular testing at diagnosis — identifying which patients have the ALK mutation that makes them candidates for this remarkable treatment.
6. AI-Assisted Cancer Detection — Becoming Clinical Reality
Artificial intelligence tools for detecting cancer in imaging are moving from research to routine clinical use at an accelerating pace in 2025.
AI-assisted mammography — reading breast cancer scans alongside or instead of radiologists — has been deployed in several health systems following studies showing it can detect cancers missed by human readers while reducing radiologist workload. Similar AI tools for lung CT scan interpretation (for lung cancer screening), cervical cancer screening, and pathology slide analysis (identifying cancer cells in tissue biopsies) have advanced from research settings toward real-world clinical deployment.
The MSK-developed SCORPIO model described above is part of a broader wave of AI integration into oncology decision-making — moving beyond diagnostics to treatment selection, response prediction, and outcomes modelling.
The promise of AI in oncology is not that it replaces clinical judgement, but that it augments it — bringing the pattern-recognition capability of models trained on millions of data points to bear on individual patient decisions.
7. Neoadjuvant Immunotherapy — Treating Earlier for Better Outcomes
One of the consistent strategic themes of 2025 oncology has been the movement of immunotherapy and targeted therapies into earlier disease settings — neoadjuvant (before surgery) and adjuvant (after surgery) use.
The principle is straightforward: treatments that are highly effective in advanced cancer are likely to be even more effective when the tumour burden is lower and the immune system is not yet exhausted. Early data from multiple trials in breast cancer, lung cancer, bladder cancer, and melanoma support this approach — with neoadjuvant checkpoint inhibitor combinations showing high rates of pathological complete response (complete disappearance of tumour at surgery) in multiple cancer types.
As cancer researcher Dr. Lesley Siu noted: "We will continue to see drugs moving into earlier disease treatment settings, because this is where we would make the biggest difference in increasing cancer cures."
What These Breakthroughs Mean for Patients
For patients currently in treatment or recently diagnosed:
Ask your oncologist about biomarker testing
many of the new precision treatments require molecular testing at diagnosis (ESR1, ALK, PD-L1, TMB) to identify who benefits most
Ask about clinical trials
several of the findings above are in Phase II or III trials actively recruiting patients; ClinicalTrials.gov lists all current trials by cancer type
Understand that progress is real
survival rates in several cancers have shifted dramatically in the past decade due to immunotherapy and targeted therapy advances; outcomes that were not possible five years ago are becoming standard of care
The breakthroughs of 2025 represent genuine scientific progress — rigorously tested, peer-reviewed, and increasingly available to patients through clinical trials and regulatory approval.
Frequently Asked Questions
What was the biggest cancer research breakthrough of 2025?
Several major advances occurred in 2025. The development of SCORPIO — an AI model predicting immunotherapy response from a routine blood test — is considered highly impactful because of its accessibility. The mRNA personalised cancer vaccine Phase 2b data and the off-the-shelf CAR NK cell therapy results were also among the most discussed findings of the year in oncology.
Are personalised mRNA cancer vaccines available to patients?
Personalised mRNA cancer vaccines are currently available through clinical trials. Moderna and Merck's mRNA-4157/V940 vaccine is in Phase 3 trials for melanoma and expanding to other cancer types. Patients interested in access can search ClinicalTrials.gov for their specific cancer type.
What is the difference between CAR-T and CAR-NK cell therapy?
CAR-T therapy uses T-cells collected from the individual patient, engineered, and reinfused — a personalised process taking weeks. CAR-NK cell therapy uses Natural Killer cells that can be manufactured in advance from a donor and stored, making them immediately available off-the-shelf. CAR-NK therapy aims to provide the benefits of cellular immunotherapy with lower cost and faster access.
What is an ESR1 mutation in breast cancer?
ESR1 mutations occur in the oestrogen receptor gene and are one of the most common mechanisms by which hormone receptor-positive breast cancers develop resistance to standard endocrine therapy. Imlunestrant, approved in 2025, specifically targets and degrades the mutated oestrogen receptor, providing a treatment option for patients whose cancer has this resistance mechanism.
How does AI help in cancer treatment?
AI in oncology is used for: early detection in imaging (mammography, CT scans), predicting which treatments a patient is likely to respond to, analysing pathology slides for cancer cell identification, and modelling patient outcomes. These tools augment clinical decision-making rather than replace physician judgement.
Comments